Molecular targeted agents such as human epidermal growth factor receptor 2 (HER2) and epidermal growth factor receptor (EGFR) monoclonal antibodies have been proven to be effective in certain GC patients; however, options are still limited, and the median overall survival (OS) for advanced GC patients is only about 1 year [3, 4]. Here, ERBB2 is linked to gastric cancer.